Novel dual BTK and JAK3 inhibitor shows preclinical efficacy against rheumatoid arthritis
Dec. 13, 2023
Rheumatoid arthritis (RA) is a systemic autoimmune disorder where Bruton tyrosine kinase (BTK) and Janus kinase 3 (JAK3) are among the most relevant signaling pathways involved.